Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events

Thrombosis and Haemostasis

Volumn 94, Issue 6, 2005, Pages 1164-1171

  Kuhle, Stefan ^a   Massicotte, Patti ^a,b   Dinyari, Maria ^b   Vegh, Patsy ^b   Mitchell, Debra ^c   Marzinotto, Velma ^b   Chan, Antony ^d   Pieniaszek, Hank ^e   Mitchell, Lesley G ^a,b  

^a STOLLERY CHILDREN S HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c LEO Pharma Inc   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e HPP Consulting and Services Inc   (United States)

Author keywords

Dosages; Low molecular weight heparin; Pediatrics; Pharmacokinetics; Treatment

Indexed keywords

TINZAPARIN;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; FEMALE; GROUPS BY AGE; HEMATOMA; HUMAN; INFANT; INJECTION PAIN; INJECTION SITE REACTION; LIVER DYSFUNCTION; MALE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN BRUISING; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; THROMBOSIS; URTICARIA;

EID: 29244488718     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th05-03-0215     Document Type: Article

References (26)

1. Andrew M, David M, Adams M et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-7.
2. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995;96: 939-43.
3. van Ommen CH, Heijboer H, Buller HR et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139: 676-81.
4. Andrew M, Marzinotto V, Massicotte P et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35: 78-83.
5. Streif W, Andrew M, Marzinotto V et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999; 94: 3007-14.
6. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
7. Massicotte P, Adams M, Marzinotto V et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128: 313-8.
8. Nohe N, Flemmer A, Rumler R et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999; 158 Suppl 3: S134-9.
9. Punzalan RC, Hillery CA, Montgomery RR et al. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000; 22: 137-42.
10. Dix D, Andrew M, Marzinotto V et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136: 439-45.
11. Laporte S, Mismetti P, Piquet P et al. Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci 1999; 8: 119-25.
12. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
13. Simonneau G, Sors H, Charbonnier B et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337: 663-9.
14. Monagle P, Michelson AD, Bovill E et al. Antithrombotic therapy in children. Chest 2001; 119: 344S-370S.
15. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker Inc.; 1982.
16. Massicotte P, Julian JA, Marzinotto V et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003; 109: 93-9.
17. Monagle P, Chan A, Massicotte P et al. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 645S-87S.
18. Kahle S, Mitchell L, Massicotte P et al. Hemostatic disorders of the newborn. In: Taeusch HW, Ballard RA, Gleason CA, editors. Avery's Diseases of the Newborn. Philadelphia: Saunders; 2004. p. 1145-79.
19. Andrew M, Vegh P, Johnston M et al. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
20. Streif W, Goebel G, Chan AK et al. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed 2003; 88: F365-70.
21. Massicotte P, Julian JA, Gent M et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109: 85-92.
22. Levine MN, Raskob G, Landefeld S et al. Hemorrhagic complications of anticoagulant treatment. Chest 1998;114: 511S-523S.
23. Prandoni P, Siragusa S, Girolami B et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low molecular weight heparin. Blood 2005; 0: 200503091
24. Christiansen HM, Lassen MR, Borris LC et al. Biologic tolerance of two different low molecular weight heparins. Semin Thromb Hemost 1991; 17: 450-4.
25. Vieira A, Berry L, Ofosu F et al. Heparin sensitivity and resistance in the neonate: an explanation. Thromb Res 1991; 63: 85-98.
26. Kuhle S, Massicotte MP, Andrew M et al. Ex-vivo thrombin generation capacity in pediatric patients receiving tinzaparin. J Thromb Haemost 2003; 1: OC421.